PR Industry - February 4, 2024
Ashfield Nordic has become Inizio Engage Nordic
In June 2023 Ashfield Nordics became Inizio Engage Nordic. A purpose-built brand, set to change the way the industry interacts with its customers, Inizio Engage now combines the strength, expertise, and proven track record of Ashfield Engage and The Creative Engagement Group into a unified global strategic, commercial, and creative engagement partner. Inizio Engage was […]
PR Industry - October 9, 2023
Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing
Houston, Texas – October 9th, 2023 — Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, […]
PR Industry - September 6, 2023
Announcing Scandinavian CRO’s new Chairman of the Board
Scandinavian CRO (SCRO) is a full-service contract research organization that helps industry and academia develop medicines and medical devices that improve patient health. For over 15 years, Founder & CEO Ulrika Hammarström has focused on building a sustainable company with a strong company culture and value-based leadership. As a two-time winner of the Gasell from […]
PR Industry - August 17, 2023
SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy
On Tuesday, 15th of August, NDA Group and SSI Strategy announced the merger of their companies, creating an industry leading life sciences consulting firm. This collaboration combines two trusted consultancies to provide end-to-end support for drug development companies, guiding them from concept to commercialization. SSI Strategy brings exceptional medical, clinical, and development expertise to complement NDA’s regulatory capabilities. Their teams, […]
PR Industry - August 7, 2023
Antibody-drug Conjugates: A Novel Paradigm for Cancer Therapy
Chemotherapy is one of the most widely used cancer therapies; however, chemotherapy often causes serious side effects. Antibody-drug conjugates (ADCs) are promisingly emerging cancer therapies that combine the effective killing power of small molecule cytotoxins and the highly specific targeting ability of monoclonal antibodies (mAbs). Thus, ADCs precisely deliver cytotoxins to tumor cells, while minimally […]
PR Industry - June 28, 2023
The new era of bispecific antibodies for cancer immunotherapy
Emerging bispecific antibodies and their targets in cancer immunotherapy in the discovery, development, preclinical, and clinical stages. Monoclonal antibodies have revolutionized cancer therapy since their introduction as therapeutics in the field. To enhance the specificity and potency of antibodies, bispecific antibodies (bsAbs) are emerging, with the ability to bind two different antigens or two different […]
